Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $17.57.
FOLD has been the subject of several analyst reports. Bank of America lowered their price target on shares of Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, May 10th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a report on Friday, May 10th. Morgan Stanley lowered their price target on shares of Amicus Therapeutics from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Friday, May 10th. Wells Fargo & Company assumed coverage on shares of Amicus Therapeutics in a report on Thursday, May 30th. They set an “overweight” rating and a $18.00 price target for the company. Finally, Guggenheim upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price for the company in a report on Tuesday, May 14th.
Read Our Latest Analysis on Amicus Therapeutics
Amicus Therapeutics Price Performance
Amicus Therapeutics (NASDAQ:FOLD – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.04. Amicus Therapeutics had a negative net margin of 34.73% and a negative return on equity of 77.08%. The company had revenue of $110.40 million during the quarter, compared to analysts’ expectations of $111.19 million. During the same quarter in the previous year, the business posted ($0.18) EPS. The firm’s revenue was up 27.9% on a year-over-year basis. On average, research analysts forecast that Amicus Therapeutics will post -0.12 earnings per share for the current fiscal year.
Insider Buying and Selling
In related news, CEO Bradley L. Campbell sold 6,100 shares of the stock in a transaction on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,866,540. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Amicus Therapeutics news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $10.07, for a total transaction of $75,525.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,928,605.78. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction on Friday, July 5th. The stock was sold at an average price of $10.00, for a total transaction of $61,000.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $8,866,540. The disclosure for this sale can be found here. 2.20% of the stock is owned by company insiders.
Hedge Funds Weigh In On Amicus Therapeutics
A number of large investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Amicus Therapeutics by 5.0% during the 4th quarter. Vanguard Group Inc. now owns 28,492,486 shares of the biopharmaceutical company’s stock worth $404,308,000 after buying an additional 1,360,613 shares during the last quarter. Perceptive Advisors LLC raised its position in Amicus Therapeutics by 1.3% during the 4th quarter. Perceptive Advisors LLC now owns 28,057,456 shares of the biopharmaceutical company’s stock worth $398,135,000 after buying an additional 364,539 shares during the last quarter. Wellington Management Group LLP increased its holdings in shares of Amicus Therapeutics by 101.9% in the 4th quarter. Wellington Management Group LLP now owns 15,190,024 shares of the biopharmaceutical company’s stock valued at $215,546,000 after purchasing an additional 7,666,335 shares in the last quarter. Janus Henderson Group PLC increased its holdings in shares of Amicus Therapeutics by 20.1% in the 1st quarter. Janus Henderson Group PLC now owns 13,814,514 shares of the biopharmaceutical company’s stock valued at $162,713,000 after purchasing an additional 2,307,385 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Amicus Therapeutics in the 4th quarter valued at about $35,915,000.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.
See Also
- Five stocks we like better than Amicus Therapeutics
- What is the Australian Securities Exchange (ASX)
- Is Crypto Cool Again? What Stocks You Should Be Watching
- Are Penny Stocks a Good Fit for Your Portfolio?
- Why Call Options Volume for These 2 Stocks Spiked Together
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- MarketBeat Week in Review – 7/22 – 7/26
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.